INTRODUCTION
============

Cardiac pacemaker activity is tightly regulated by the autonomic nervous system. The sympathetic nervous system enhances heart rate and contractility, whereas the parasympathetic (vagal) inputs slow pacemaking. The dominant pacemaker region of the heart, the sinoatrial node (SAN), is innervated by a rich and complex network of vagal nerve endings ([@bib33], [@bib34]). Parasympathetic regulation of SAN pacemaker activity is initiated when vagally released acetylcholine (ACh) binds to muscarinic M~2~ receptors, which promotes dissociation of βγ subunit complexes, leading to direct opening of the G-protein--gated inwardly rectifying K^+^ channel (Girk/Kir) *I~KACh~* ([@bib21]; [@bib40]). Activation of muscarinic receptors negatively regulates other ion channels involved in heart automaticity, such as hyperpolarization-activated f (hyperpolarization-activated cyclic nucleotide--gated channel \[HCN\])-channels underlying the *I~f~* current ([@bib8]) and L-type Ca^2+^ channels (*I~Ca,L~*; [@bib35]; [@bib45]; [@bib27]), as well as ryanodine receptor--mediated Ca^2+^ release ([@bib22]). All of these ionic mechanisms are thus potentially involved in the cholinergic regulation of heart rate, but their relative importance is still a matter of debate ([@bib27]).

*I~KACh~* is strongly expressed in the SAN, atria, and atrioventricular node ([@bib12]; [@bib32]; [@bib23]; [@bib9]; [@bib24]). Neuronal and cardiac Girk channels are homo- and heterotetrameric complexes formed by subunits encoded by four genes named Girk1--4 (Kir3.1--4; [@bib38]). The heart expresses Girk1 and Girk4 genes ([@bib40]; [@bib10]), and cardiac *I~KACh~* channels are complexes consisting of Girk1 and Girk4 ([@bib40]). However, the Girk1 subunit requires coexpression of another Girk subunit to be targeted at the cell membrane ([@bib18]). Consequently, ablation of Girk4 subunits in mice leads to a complete loss of *I~KACh~* current in atrial myocytes ([@bib39]).

The heart rate of Girk4 knockout mice (Girk4^−/−^) shows reduced variability and a diminished responsiveness to pharmacological stimulation of the baroreflex and adenosine receptors ([@bib39]). However, the physiological effects of Girk4 inactivation on the SAN *I~KACh~* and on the cholinergic regulation of SAN pacemaking have not been investigated. Here we show that Girk4 inactivation abolished SAN *I~KACh~* and reduced cholinergic regulation of pacemaker activity in isolated SAN cells and intact hearts. In Girk4^−/−^ mice, *I~KACh~* was required for normal recovery of resting heart rate after stress, physical exercise, or direct pharmacological stimulation of pacemaking via β-adrenergic receptors. Our study analyzes the impact of *I~KACh~* loss of function in the cholinergic regulation of SAN pacemaking and uncovers a previously unexpected role for this channel in heart rate regulation.

MATERIALS AND METHODS
=====================

The investigation conforms to the European directives (86/609/CEE) and the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH publication no. 85-23, revised 1996). The French Ministry of Agriculture and the local Ethical Committee of the University of Montpellier 1 & 2 approved all procedures with animals.

Girk4^−/−^ mouse strain
-----------------------

Before starting the study, we obtained experimental Girk4^−/−^ animals by crossing mice from the original mutant colony ([@bib39]) with mice of C57B6/J genetic background from Charles River in the free of specific pathogenic organisms (EOPS) animal facility of the Réseau d'Animalèrie de Montpellier (RAM) at the Institut de Génetique Humaine (Montpellier, France). We next backcrossed the offspring for 10 generations on C57B6/J mice before starting the study. Animals were given ad libitum access to food and drinking water and were maintained in a 12-h light--dark cycle (light, 8:30 a.m. to 8:30 p.m.).

Staining of SAN tissue and image analysis
-----------------------------------------

We used isolated mouse atrio-nodal (SAN-atrium) preparations in which the right atrium remained intact with SAN to facilitate orientation determination and to preserve tissue integrity. WT and Girk4^−/−^ mice were dissected and placed immediately into 4% paraformaldehyde for 20 min at room temperature, followed by soaking in 1× PBS for several hours. The tissue was suspended in 250 µl of 2% BSA (Sigma-Aldrich), 500 µg/ml digitonin (Sigma-Aldrich) containing an anti-HCN4 monoclonal antibody (1:100 rat, SHG 1E5; Santa Cruz Biotechnology, Inc.), anti-Girk4 polyclonal antibody (1:100 goat, A-14; Santa Cruz Biotechnology, Inc.), or anti-Girk1 polyclonal antibody (1:100 rabbit, H-145; Santa Cruz Biotechnology, Inc.), and 0.002% Na azide to prevent bacterial growth. Tissues were incubated for 66 h at room temperature with very gentle shaking in a Lab-Tek II chamber slide (Thermo Fisher Scientific). The tissue was rinsed 5 × 500 µl (1× PBS) over a 5-h period at room temperature. The procedure was repeated again, but this time the tissue was incubated with chicken anti--rat Alexa Fluor 647 (1:500; Molecular Probes), donkey anti--goat Alexa Fluor 568 (1:500; Molecular Probes), and donkey anti--rabbit Alexa Fluor 488 secondaries (1:500; Molecular Probes). The tissue was placed in ProLong Gold (Invitrogen), and a portion of the right atrium was removed and discarded to simplify mounting of the sample. A glass coverslip was gently placed over the sample with the epicardial side face up. Images were taken with a confocal microscope (TCS LSI; Leica) at the Montpellier RIO Imaging facility of the Arnaud de Villeneuve Campus. Analysis of images was performed with the JaCoP plugin for ImageJ (National Institutes of Health; [@bib2]). Appropriate threshold levels were manually adjusted, and the Manders coefficient of colocalization between HCN4 and Girk4, as well as between HCN4 and Girk1 was calculated using JaCoP software.

Isolation of SAN cells
----------------------

SAN cells were isolated as described previously ([@bib26]). WT and Girk4^−/−^ mice were killed by cervical dislocation under general anesthesia consisting of 0.01 mg/g xylazine (2% Rompun; Bayer AG) and 0.1 mg/g ketamine (Imalgène; Merial), and beating hearts were quickly removed. The SAN region was excised in warmed (35°C) Tyrode's solution containing (in mM): 140.0 NaCl, 5.4 KCl, 1.8 CaCl~2~, 1.0 MgCl~2~, 5.0 HEPES-NaOH, and 5.5 [d]{.smallcaps}-glucose (adjusted to pH 7.4 with NaOH) and cut in tissue strips. Strips were then transferred into a low-Ca^2+^, low-Mg^2+^ solution containing (in mM): 140.0 NaCl, 5.4 KCl, 0.5 MgCl~2~, 0.2 CaCl~2~, 1.2 KH~2~PO~4~, 50.0 taurine, 5.5 [d]{.smallcaps}-glucose, 1.0 mg/ml BSA, and 5.0 HEPES-NaOH (adjusted to pH 6.9 with NaOH). The tissue was enzymatically digested by adding 229 U/ml collagenase type II (Worthington Biochemical Corporation), 1.9 U/ml elastase (Boehringer Mannheim), 0.9 U/ml protease (Sigma-Aldrich), 1 mg/ml BSA, and 200 µM CaCl~2~. Tissue digestion was performed for a variable time of 9--13 min at 35°C with manual agitation using a flame-forged Pasteur pipette. Tissue strips were then washed and transferred into a medium containing (in mM): 70.0 [l]{.smallcaps}-glutamic acid, 20.0 KCl, 80.0 KOH, 10.0 (±)D-β-OH-butyric acid, 10.0 KH~2~PO~4~, 10.0 taurine, 1 mg/ml BSA, and 10.0 HEPES-KOH, pH 7.4 with KOH. SAN cells were manually dissociated in KB solution at 35°C for ∼10 min. Cellular automaticity was recovered by readapting the cells to physiological extracellular Na^+^ and Ca^2+^ concentrations by adding aliquots of solutions containing (in mM): 10.0 NaCl, 1.8 CaCl~2~, and, subsequently, normal Tyrode's solution containing 1 mg/ml BSA. The final storage solution contained (in mM): 100.0 NaCl, 35.0 KCl, 1.3 CaCl~2~, 0.7 MgCl~2~, 14.0 [l]{.smallcaps}-glutamic acid, 2.0 (±)D-β-OH-butyric acid, 2.0 KH~2~PO~4~, 2.0 taurine, and 1.0 mg/ml BSA, pH 7.4. Cells were then stored at room temperature until use. All chemicals were obtained from Sigma-Aldrich, except for the (±)D-β-OH-butyric acid, which was purchased from Fluka Chemika. For electrophysiological recording, SAN cells in the storage solution were harvested in special custom-made recording plexiglass chambers with glass bottoms for proper cell attachment. The storage solution was continuously rinsed with normal Tyrode's solution warmed at 36°C before recording.

Patch-clamp recordings of mouse SAN cells
-----------------------------------------

The basal extracellular Tyrode's solution used in all recordings contained (in mM): 140.0 NaCl, 5.4 KCl, 1.8 CaCl~2~, 1.0 MgCl~2~, 5.0 HEPES-NaOH, 5.5 and [d]{.smallcaps}-glucose (adjusted to pH 7.4 with NaOH). *I~KACh~* and *I~f~* were recorded using the standard whole-cell configuration. Patch-clamp electrodes had a resistance of 4--5 MΩ when filled with an intracellular solution containing (in mM): 130.0 K^+^-aspartate; 10.0 NaCl; 2.0 ATP-Na^+^ salt, 6.6 creatine phosphate, 0.1 GTP-Mg^2+^, 0.04 CaCl~2~ (pCa = 7.0), and 10.0 HEPES-KOH (adjusted to pH 7.2 with KOH). For recording *I~Ca,L~*, K^+^-aspartate in the intracellular solution was replaced with an equal amount of CsCl. The extracellular solution contained (in mM) 130 TEA-Cl, 2 CaCl~2~, 1 MgCl~2~, 10 4-amino-pyridine, and 25 HEPES (adjusted to pH 7.4 with TEA-OH). A correction of 9.8 mV because of liquid junction potential was applied in *I~Ca,L~* recordings (calculated with Patcher's Power Tools; Wavemetrics). All experiments were performed at 36°C. Pacemaker activity of SAN cells was recorded under perforated patch conditions by adding 50 µM β-escin to the pipette solution.

Isolated Langendorff perfused intact hearts
-------------------------------------------

Excised hearts were quickly mounted on a Langendorff apparatus (Isolated heart system; EMKA Technologies) at a constant pressure of 80 mm Hg with normal Tyrode's solution. Perfused hearts were immersed in the water-jacked bath and maintained at 36°C. The electrocardiogram (ECG) was continuously recorded by Ag-AgCl electrodes positioned on the epicardial side of the right atrium close to the SAN area and near the apex. The heart rate was allowed to stabilize for at least 30 min before perfusion of ACh and/or isoproterenol (ISO).

Telemetric recordings of ECG and analysis
-----------------------------------------

For telemetric ECG recording, adult male mice were anesthetized with 2% isoflurane. A midline incision was made on the back along the spine to insert a telemetric transmitter allowing simultaneous recording of ECG and home-cage activity (TA10EA-F20; Data Sciences International) into a subcutaneous pocket with paired wire electrodes placed over the thorax (chest bipolar ECG lead). Local anesthesia was obtained with 1% lidocaine injected subcutaneously at the sites of electrodes and transmitter implantation. To manage possible post-surgery pain, Advil (7 ml/l paracetamol and ibuprofen) was added to the drinking water for 4 d after implantation. Experiments were initiated at least 8 d after recovery from surgical implantation. Mice were housed in individual cages with ad libitum access to food and water and were exposed to standard 12-h light--dark cycles in a thermostatically controlled room. ECG signals were recorded using a telemetry receiver and an analogue to digital conversion data acquisition system for display and analysis by Dataquest A.R.T.TM software (Data Sciences International). Heart rates were determined from inter-beat (RR) intervals of the ECG. Mean heart rate values were obtained in each mouse for an overall 24-h period from 8:30 a.m. to 8:30 p.m. and analyzed as previously described by [@bib1]. Heart rate variability (HRV) spectra of WT and Girk4^−/−^ mice were analyzed from RR intervals according to [@bib39]. For drug administration or physical exercise experiments, mean heart rate values were calculated in each mouse by analyzing 5-min periods. ECG parameters were measured with ECG Auto 1.5.7 software.

Swimming tests were performed by using homemade plexiglass boxes of 15 × 32 cm and of 13 cm in height filled with prewarmed water (32°C) 9 cm deep. For exercise experiments, we used a two-mouse treadmill (model LE8709; BioSeb). Recovery to resting heart rate was assessed as the time to recovery (τ~r~) calculated by fitting experimental data according to the one-phase-decay equation: y = e^(−k\ ×\ t)^, where y is the heart rate value in beats per minute (bpm) at a given time, t is time, and k = 1/τ~r~.

Statistical analysis
--------------------

Two-way ANOVA was used for comparisons between genotypes and multiple ACh concentrations. When needed, Sidak's multiple comparisons test was performed. Unpaired Student's *t* test was used in all other analysis. Data are represented as the mean ± the SEM. Analysis was performed using Prism 6.0 (GraphPad Software).

Online supplemental material
----------------------------

The supplemental text describes the mRNA extraction and RT-PCR protocol. Fig. S1 shows the expression and distribution of Girk subunits in different mouse tissues by RT-PCR. Fig. S2 shows the heart rate variation in Girk4^−/−^ mice after administration of atropine, propranolol, and atropine plus propranolol. Fig. S3 shows the recovery of heart rate in Girk4^−/−^ mice after treadmill test or intraperitoneal injection of atropine. Table S1 shows the action potential parameters in WT and Girk4^−/−^ SAN cells before and after perfusion of 0.003, 0.01, and 0.05 µM ACh. Online supplemental material is available at <http://www.jgp.org/cgi/content/full/jgp.201310996/DC1>.

RESULTS
=======

Expression of Girk4 in mouse SAN
--------------------------------

Atrial myocardium expresses Girk1 and Girk4 subunits. Loss of Girk4 abolishes *I~KACh~* single channel openings in cell-attached and inside-out patches of atrial cells of Girk4^−/−^ mice ([@bib39]). We thus studied the distribution of Girk4 immunoreactivity in the intact SAN connected to the right atrium by macro-confocal microscopy. To define unambiguously the position of the SAN territory, as well as SAN pacemaker cells within the intact SAN-atrium preparation in WT and Girk4^−/−^ hearts, we used anti-HCN4 immunoreactivity as a specific marker of spontaneously active SAN cells ([@bib43]; [@bib6]). Staining of the intact SAN showed that HCN4-positive pacemaker cells were present in the cranial pole of the SAN, close to its boundary with the crista terminalis, and that their distribution was particularly dense in the region of dominant pacemaking identified by [@bib37]; [Fig. 1 A](#fig1){ref-type="fig"}, left). We did not observe differences in the abundance, distribution, or location of HCN4-positive cells in Girk4^−/−^ SAN preparations.

![Distribution and localization of anti-Girk immunoreactivity in isolated mouse atrio-sinus preparations. (A) Representative images of *n* = 3 isolated SAN right atrium (RA) preparations (endocardial side) double stained with HCN4 and Girk4 antibodies. CT, crista terminalis; IVC and SVC, inferior and superior vena cava, respectively. (B) Close-up views of pacemaker cells within the SAN stained with HCN4, Girk4, or Girk1 antibodies. Individual HCN4-positive cells within the SAN region of WT hearts showed strong membrane-associated Girk4 and Girk1 immunoreactivity (top). Girk4^−/−^ SAN cells displayed HCN4-positive and Girk4-negative staining and no membrane-bound Girk1 (bottom). Bars, 10 µm.](JGP_201310996_Fig1){#fig1}

Girk4 immunoreactivity was present in both the SAN and right atrium ([Fig. 1 A](#fig1){ref-type="fig"}, middle). In the SAN region, Girk4 and HCN4 immunoreactivity largely overlapped ([Fig. 1 A](#fig1){ref-type="fig"}, right). Close-up views of pacemaker cells within the SAN showed that HCN4 immunoreactivity localized along the myocyte plasmalemma as reported previously in mouse SAN ([Fig. 1 B](#fig1){ref-type="fig"}, left; [@bib15]). Individual HCN4-positive cells within the SAN region of WT hearts showed strong membrane-associated Girk4 and Girk1 immunoreactivity ([Fig. 1 B](#fig1){ref-type="fig"}, middle and right). Girk4 and Girk1 immunoreactivity overlapped with HCN4 in the field of view in WT SAN (Manders coefficient of 0.46 ± 0.04 for Girk4 and 0.5 ± 0.05 \[*n* = 5\] for Girk1 immunoreactivity). In contrast, Girk4^−/−^ SAN preparations displayed HCN4-positive and Girk4-negative cells (Manders coefficient of 0.004 ± 0.02; *n* = 3). In agreement with the notion that Girk1 is not targeted to the membrane in the absence of Girk4, we failed to observe membrane-bound Girk1 immunoreactivity in Girk4^−/−^ SAN cells ([Fig. 1 B](#fig1){ref-type="fig"}, right).

Because it is known that the SAN gene expression profile may include ion channel genes that are not expressed in atria or ventricles ([@bib29]), we tested the potential expression and distribution of mRNA coding for Girk2 or Girk3 subunits in the mouse SAN by RT-PCR ([Fig. S1 A](http://www.jgp.org/cgi/content/full/jgp.201310996/DC1){#supp1}). To compare the expression of Girk isoforms in cardiac and neuronal tissues, we purified mRNA from tissue samples of the SAN, right atrium, left ventricle, brain cortex, and cerebellum. Myocardial tissues and the SAN expressed only Girk4 and Girk1 mRNA, whereas Girk2 and Girk3 were expressed in the cortex and cerebellum, respectively. We did not find Girk4 mRNA in SAN preparations of Girk4^−/−^ mice (Fig. S1).

Pacemaker cells from Girk4^−/−^ mice lack *I~KACh~*
---------------------------------------------------

We studied the expression of *I~KACh~* current in WT and Girk4^−/−^ SAN cells ([Fig. 2](#fig2){ref-type="fig"}). We recorded *I~KACh~* by holding the membrane voltage at −35 mV and then perfusing ACh for 20 s before returning to control solution ([Fig. 2 A](#fig2){ref-type="fig"}). In WT cells, ACh dose-dependently increased the *I~KACh~* current ([Fig. 2, A and B](#fig2){ref-type="fig"}). At concentrations of ACh \>1 µM, the peak *I~KACh~* current decreased as the result of channel desensitization ([Fig. 2 B](#fig2){ref-type="fig"}; [@bib3]; [@bib44]). We failed to observe detectable residual *I~KACh~* in Girk4^−/−^ SAN cells in the full range of ACh concentrations tested ([Fig. 2, A and B](#fig2){ref-type="fig"}). We also did not observe *I~KACh~* in atrial cells that were isolated in parallel from the same Girk4^−/−^ hearts used for recordings of SAN cells (not depicted). We conclude that inactivation of Girk4 channels abolished *I~KACh~* in mouse SAN pacemaker cells.

![Inactivation of Girk4 channels ablates *I~KACh~* in mouse SAN cells. (A) Sample traces of *I~KACh~* current in WT and Girk4^−/−^ SAN cells. *I~KACh~* was activated by ACh in WT and Girk4^−/−^ SAN cells. Arrows indicate the period of time for which ACh was added. (B) *I~KACh~* density at different ACh concentrations in SAN cells from WT (0.003--10 µM; *n* = 4--16; closed circles) and Girk4^−/−^ (0.003--10 µM; *n* = 3--13; open circles) mice. Error bars represent SEM. Statistical symbols: \*, P \< 0.05; and \*\*, P \< 0.01.](JGP_201310996_Fig2){#fig2}

We also tested whether inactivation of Girk4 affected the density of *I~f~* and *I~Ca,L~*, which are potentially involved in parasympathetic regulation of heart rate ([@bib27]). We did not find significant difference in the peak densities, activation, and kinetics of *I~f~* ([Fig. 3 A](#fig3){ref-type="fig"}) or *I~Ca,L~* ([Fig. 3 B](#fig3){ref-type="fig"}) between WT and in Girk4^−/−^ SAN cells.

![Loss of *I~KACh~* in Girk4^−/−^ mice did not affect functional expression of *I~f~* and *I~Ca,L~*. (A, left) Isochronal current to voltage curves for *I~f~* in SAN cells from WT (*n* = 8; closed circles) and Girk4^−/−^ (*n* = 10; open circles) mice. (right) Representative voltage-clamp recordings of *I~f~* in isolated WT and Girk4^−/−^ SAN cells. Applying hyperpolarizing voltage steps from a holding potential of −30 mV evoked *I~f~* current. (B, left) Isochronal current to voltage curves of *I~Ca,L~* in SAN cells from WT (*n* = 12; closed circles) and Girk4^−/−^ (*n* = 9; open circles). (right) Sample traces of *I~Ca,L~* in SAN cells from WT and Girk4^−/−^ mice. Recordings were obtained by applying depolarizing voltage steps from a holding potential of −55 mV. Voltage-clamp protocols are shown below the traces, and the dashed lines indicate the zero voltage. Error bars represent SEM.](JGP_201310996_Fig3){#fig3}

Loss of *I~KACh~* in Girk4^−/−^ mice reduces cholinergic regulation of pacemaker activity in SAN cells and in isolated intact hearts
------------------------------------------------------------------------------------------------------------------------------------

To investigate how the loss of *I~KACh~* affects the negative chronotropic effect of ACh on pacemaker activity, we recorded automaticity of SAN cells from WT and Girk4^−/−^ mice ([Fig. 4](#fig4){ref-type="fig"}). To mimic moderate basal activation of the β-adrenergic signaling pathway, we added 2 nM ISO to the Tyrode's solution, a concentration inducing a submaximal positive chronotropic effect on SAN cell pacemaking ([@bib1]). Under these conditions, the basal pacing rate, action potential threshold and duration, and maximum diastolic potential (MDP) of WT and Girk4^−/−^ SAN cells did not significantly differ ([Table S1](http://www.jgp.org/cgi/content/full/jgp.201310996/DC1){#supp2}). In WT cells, ACh dose-dependently slowed pacemaker activity, with effects evident at 0.003 µM and maximal at 0.05 µM ([Fig. 4 A](#fig4){ref-type="fig"}). At 0.003 µM, ACh-induced pacemaker rate reduction did not differ significantly between WT and Girk4^−/−^ SAN cells, even though we observed a trend toward an increase in WT (17% in WT and 10% in Girk4^−/−^ SAN cells; [Fig. 4, A--C](#fig4){ref-type="fig"}; and Table S1). At 0.01 µM ACh, the absence of Girk4 resulted in an obvious difference in rate reduction, from 71% in WT to 36% in Girk4^−/−^ SAN cells ([Fig. 4, A--C](#fig4){ref-type="fig"}). Finally, ACh induced a strong (52%) negative chronotropic effect on Girk4^−/−^ SAN cells at 0.05 µM, but contrary to WT cells, we never observed cessation of pacemaker activity in knockout cells at this concentration. MDP was significant hyperpolarized in WT SAN cells challenged with 0.05 µM ACh ([Fig. 4 A](#fig4){ref-type="fig"} and Fig. S1 B); membrane hyperpolarization persisted for ∼4 s before settling to a stable membrane voltage that did not significantly differ from that recorded before ACh superfusion (Fig. S1 B). ACh reduced the slope of the diastolic depolarization in WT and Girk4^−/−^ SAN cells at all concentrations \>0.01 µM (Table S1). ACh did not affect the action potential threshold, velocity, duration, or MDP of WT and Girk4^−/−^ SAN cells (Table S1).

![Cholinergic regulation of pacemaker activity in WT and Girk4^−/−^ SAN cells. (A) Examples of spontaneous action potentials recorded in SAN cells from WT and Girk4^−/−^ hearts in control conditions (black traces) and after perfusion of ACh (gray traces) at the indicated doses. (B) Histograms of pacing rate of WT (closed bars) and Girk4^−/−^ (open bars) SAN cells in control conditions (WT *n* = 6; Girk4^−/−^ *n* = 6) and after perfusion of 0.003 (WT *n* = 5; Girk4^−/−^ *n* = 7), 0.01 (WT *n* = 18; Girk4^−/−^ *n* = 10), and 0.05 µM ACh (WT *n* = 5; Girk4^−/−^ *n* = 7). (C) Dose--response relation of the percentage of slowing of pacemaker rate by ACh in WT (closed circles) and Girk4^−/−^ (open circles) SAN cells. At 0.01 µM ACh, inactivation of Girk4 channels significantly reduced the negative chronotropic effect from 67% in WT to 26% in Girk4^−/−^ SAN cells. At 0.05 µM ACh, pacing was absent in WT, whereas it was reduced to ∼50% in Girk4^−/−^ SAN cells. Error bars represent SEM. Statistical symbols: \*\*, P \< 0.01; and \*\*\*, P \< 0.001.](JGP_201310996_Fig4){#fig4}

We next investigated the impact of *I~KACh~* ablation on the negative chronotropic effect of ACh in isolated Langendorff-perfused intact hearts ([Fig. 5](#fig5){ref-type="fig"}). At concentrations \< 0.3 µM, ACh similarly slowed the beating rate of WT and Girk4^−/−^ hearts ([Fig. 5, A and B](#fig5){ref-type="fig"}). Increasing ACh concentrations up to 10 µM dose-dependently reduced beating rates of WT hearts (53% decrease in beating rate). In contrast, the negative chronotropic response of Girk4^−/−^ hearts to ACh at doses ranging from 0.3 to 10 µM did not significantly increase further (19%), indicating that loss of *I~KACh~* induced saturation of the maximal negative chronotropic response at moderate doses of ACh. Collectively, these observations indicate that *I~KACh~* is an important determinant of cholinergic regulation of pacemaker activity in both isolated SAN cells and intact Langendorff-perfused hearts.

![Negative chronotropic response to ACh of isolated WT and Girk4^−/−^ hearts. (A and B) Dose--response relations expressed as absolute values (bpm; A) or percentage of heart rate (HR) slowing (B) by ACh in *n* = 7 WT (closed bars and circles) and *n* = 8 Girk4^−/−^ Langendorff-perfused hearts (open bars and circles). (C) Sample traces of ECGs recorded from Langendorff-perfused hearts at baseline and after 0.3 µM ACh in WT and Girk4^−/−^. Note that reduction in heart rate was more pronounced in WT than in Girk4^−/−^ hearts. Error bars represent SEM. Statistical symbols: \*, P \< 0.05.](JGP_201310996_Fig5){#fig5}

Heart rate regulation in Girk4^−/−^ mice
----------------------------------------

To investigate the consequences of *I~KACh~* ablation on heart rate regulation in vivo, we recorded ECGs of freely moving WT and Girk4^−/−^ mice by telemetry ([Fig. 6 A](#fig6){ref-type="fig"}). WT and Girk4^−/−^ mice had similar spontaneous activities in the home cage (not depicted; in agreement with previous observations), indicating that Girk4 inactivation does not affect locomotor activity ([@bib41]). Although there was normal high-frequency variation of heart rate (HRV) in WT, HRV in Girk4^−/−^ mice varied on a slower time scale ([Fig. 6, B and C](#fig6){ref-type="fig"}). Consistent with previous observations in Girk4^−/−^ mice of pure 129Sv/J or mixed (129Sv/J/C57B6/J) genetic backgrounds ([@bib39]), both the high- and low-frequency spectral components of HRV were reduced in our Girk4^−/−^ mice ([Fig. 6, D and E](#fig6){ref-type="fig"}; [@bib39]).

![Heart rate in Girk4^−/−^ mice. (A) Sample traces of ECGs recorded in freely moving WT and Girk4^−/−^ mice. (B and C) Dot plots of beat to beat variability (in bpm) of heart rate (HR) of WT (B) and Girk4^−/−^ (C) mice for a 5-min ECG recording epoch. The dashed lines indicate the averaged heart rate. (D and E) Bar graphs showing averaged low-frequency (LF; D) and high-frequency (HF; E) power spectra of HRV in WT (*n* = 10) and Girk4^−/−^ (*n* = 9) mice for recordings shown in B and C. (F) Histogram showing the distribution of normalized averaged heart rates in a 24-h period of telemetric ECG recordings in WT (*n* = 10; black line) and Girk4^−/−^ (*n* = 9; gray line) mice. For a given mouse, individual heart rate values were calculated every 20 s over the 24-h recording and then normalized to the maximal heart rate recorded for the mouse to allow comparison between WT and Girk4^−/−^ animals. Note that the two distributions have similar shapes, but that Girk4^−/−^ heart rates are shifted toward higher values. (G) Relationship between heart rate and spontaneous home cage activity (rate to activity relationship) of WT (closed bars) and Girk4^−/−^ mice (open bars). Activity values are defined as arbitrary units (A.U.) and have been binned in six intervals of increasing activity. Binning was adjusted to obtain maximal resolution of the heart rate to activity relationship. (H) Similarity in the range of heart rate regulation as a function of activity in WT and Girk4^−/−^ mice. For each animal, the heart rate corresponding to bin 1 (lowest activity) was subtracted from the heart rate recorded at other degrees of activity. (I) Averaged heart rate measured over a 24-h recording in Girk4^−/−^ (583 ± 11 bpm; *n* = 9; open bars) and WT mice (539 ± 10 bpm; *n* = 10; closed bars; P \< 0.05). (J) Range of heart rate regulation calculated from the differences between the maximum and minimum heart rate in each mouse recorded over the 24-h recording period. Error bars represent SEM. Statistical symbols: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; and \*\*\*\*, P \< 0.0001.](JGP_201310996_Fig6){#fig6}

We recorded significantly higher heart rates in Girk4^−/−^ mice in comparison with that of WT mice over a typical 24-h recording period ([Fig. 6, F--J](#fig6){ref-type="fig"}). Indeed, the distribution of heart rates of Girk4^−/−^ mice was shifted to higher values ([Fig. 6 F](#fig6){ref-type="fig"}), and elevated heart rate in Girk4^−/−^ mice was present at all degrees of spontaneous activity in the home cage ([Fig. 6 G](#fig6){ref-type="fig"}). The rate to activity relationship of Girk4^−/−^ mice was similar to that of WT counterparts ([Fig. 6 G](#fig6){ref-type="fig"}), indicating that mild tachycardia was caused by a reduced cholinergic response of SAN pacemaker activity rather than by an elevation of sympathetic tone in knockout animals. In agreement with this hypothesis, we observed similar increases in heart rate for any increase in spontaneous activity in WT and Girk4^−/−^ mice ([Fig. 6 H](#fig6){ref-type="fig"}). Also, the difference between averaged maximal and minimal daily heart rates was similar in WT and Girk4^−/−^ mice, demonstrating that, in spite of reduced HRV, the relative degree of regulation of daily heart rate was conserved after *I~KACh~* ablation ([Fig. 6, I and J](#fig6){ref-type="fig"}).

To further test whether elevated heart rate in knockout mice was caused by loss of function of *I~KACh~* in the SAN, we measured heart rates after systemic administration (intraperitoneally) of atropine or propranolol. We recorded similar heart rates in WT and Girk4^−/−^ mice after inhibition of vagal input by administration of atropine, an observation which showed that sympathetic tone was not altered in Girk4^−/−^ mice ([Table 1, A](#tbl1a){ref-type="table"} and [B](#tbl1b){ref-type="table"}, and [Fig. S2](http://www.jgp.org/cgi/content/full/jgp.201310996/DC1){#supp3}). Similar heart rates were also observed after blockade of sympathetic input by propranolol or combined injection of these two drugs, indicating that vagal tone did not differ between WT and Girk4^−/−^ mice ([Table 1, A](#tbl1a){ref-type="table"} and [B](#tbl1b){ref-type="table"}, and Fig. S2). These observations indicate that increased heart rates of Girk4^−/−^ mice could not be ascribed to dysfunction of the sympathetic or vagal branches of the autonomic nervous system (Fig. S2). Furthermore, we did not observe significant differences in other parameters of the ECG waveform in comparing Girk4^−/−^ mice with their WT counterparts ([Table 1, A](#tbl1a){ref-type="table"} and [B](#tbl1b){ref-type="table"}, and Fig. S2).

###### 

ECG interval values

  Conditions          PR       QT       QRS      QTc
  ------------------- -------- -------- -------- --------
                      *ms*     *ms*     *ms*     *ms*
  WT~NaCl~            38 ± 1   47 ± 2   11 ± 1   44 ± 2
  Girk4^−/−^~NaCl~    36 ± 1   49 ± 2   11 ± 1   47 ± 2
  WT~Atrop~           34 ± 1   43 ± 3   10 ± 1   45 ± 2
  Girk4^−/−^~Atrop~   34 ± 1   44 ± 2   11 ± 1   46 ± 2
  WT~Prop~            40 ± 2   55 ± 2   10 ± 1   42 ± 1
  Girk4^−/−^~Prop~    41 ± 1   51 ± 2   10 ± 1   45 ± 2

See legend below [Table 1 B](#tbl1b){ref-type="table"}.

###### 

Statistical analysis of RR and PR ECG intervals

  Conditions          RR/PR                                                 
  ------------------- ------- ----------- --------------- ----------------- -----------------
  WT~NaCl~            NS/NS   \<0.05/NS   \<0.01/\<0.05   \<0.01/NS         \<0.001/NS
  Girk4^−/−^~NaCl~            NS/NS       \<0.05/NS       \<0.001/NS        \<0.001/\<0.01
  WT~Atrop~                               NS/NS           \<0.001/\<0.01    \<0.001/\<0.001
  Girk4^−/−^~Atrop~                                       \<0.001/\<0.001   \<0.001/\<0.001
  WT~Prop~                                                                  NS/NS

Atrop, atropine; Prop, propranolol. ECG interval values in WT and Girk4^−/−^ mice under control conditions (intraperitoneal injection of NaCl) or after systemic administration of 0.5 mg/kg atropine or 5 mg/kg propranolol are shown.

Next, we studied the effects of *I~KACh~* loss in heart rate regulation under conditions of forced physical exercise. First, we recorded heart rate during a period of stress associated with physical activity (forced swim; [@bib19]; [@bib13]). Heart rate was measured during a fixed exercise period, consisting of 5 min of swimming followed by 4 h of rest to recover basal heart rate in the home cage ([@bib19]). Both WT and Girk4^−/−^ mice reached similar maximal heart rates during the 5-min swimming period ([Fig. 7 A](#fig7){ref-type="fig"}). However, WT mice returned to resting heart rates more rapidly than Girk4^−/−^ mice; heart rates of WT mice reached resting levels after ∼55 min (τ~r~ = 33 ± 7 min), whereas \>100 min were necessary for Girk4^−/−^ mice to recover resting heart rates (τ~r~ = 58 ± 5 min; [Fig. 7 A](#fig7){ref-type="fig"}, inset). Similarly, on treadmill tests ([@bib14]), WT and Girk4^−/−^ mice ran for 5 min followed by a 4-h resting period. Similar to what was observed during the swimming test, knockout mice exhibited longer time to recovery of resting heart rates than their WT counterparts (τ~r~ = 17 ± 2 min in *n* = 6 WT and τ~r~ = 41 ± 11 min in *n* = 4 Girk4^−/−^ mice; P \< 0.05; [Fig. S3 A](http://www.jgp.org/cgi/content/full/jgp.201310996/DC1){#supp4}).

![Recovery of resting heart rate in Girk4^−/−^ mice. (A and B) After swimming test (A) and upon intraperitoneal injection of ISO (B). (A, left) Swimming test (5 min) was used to monitor heart rate (HR) during physical exercise of WT (*n* = 5; closed circles) and Girk4^−/−^ (*n* = 6; open circles) mice. Continuous lines represent fitting of experimental data points to calculate τ~r~ of recovery. Dashed lines represent the basal heart rate before swimming test in WT (black) and Girk4^−/−^ (gray) mice. Averaged τ~r~ for WT and Girk4^−/−^ mice is reported in the insets. (right) Samples ECG traces from WT and Girk4^−/−^ mice at rest (before swimming) and 85 min after swimming. Note that at 85 min in Girk4^−/−^ but not in WT mice, heart rate was still higher than the heart rate in the resting condition. (B, left) Basal heart rate recovery after direct activation of β-adrenergic receptors by 0.1 mg/kg ISO in WT (*n* = 15; closed circles) and Girk4^−/−^ (*n* = 11; open circles) mice. Dashed lines represent the basal heart rate before injection of ISO in WT (black) and Girk4^−/−^ (gray) mice. Averaged τ~r~ for WT and Girk4^−/−^ mice is reported in the inset. (right) Samples ECG traces from WT and Girk4^−/−^ mice under basal conditions and 60 min after ISO injection. At min 60 in Girk4^−/−^ mice but not in WT, heart rate was still higher than the basal heart rate. Error bars represent SEM. Statistical symbols: \*, P \< 0.05.](JGP_201310996_Fig7){#fig7}

To test whether the difference in heart rate recovery could be reproduced by direct pharmacological activation of β-adrenergic receptors, we investigated the responsiveness of heart rate in vivo after systemic administration of 0.1 mg/kg ISO. Similar to what we observed with physical activity, WT and Girk4^−/−^ mice reached comparable maximal heart rates after injection of ISO. Again, recovery of basal heart rate after ISO injection was longer in Girk4^−/−^ than in WT mice ([Fig. 7 B](#fig7){ref-type="fig"}). In contrast, injection of atropine, which elevates heart rate by blocking muscarinic receptors, similarly increased heart rates in WT and Girk4^−/−^ mice, but the recovery of basal heart rate did not differ significantly in the two mouse strains (Fig. S3 B).

We then investigated whether the delay in basal heart rate recovery observed in Girk4^−/−^ mice could also be recorded in isolated hearts ([Fig. 8 A](#fig8){ref-type="fig"}). Because it was possible that β-adrenergic tone could persist, we recorded the time course of the ACh-mediated negative chronotropic effect under persistent β-adrenergic activation ([Fig. 8 B](#fig8){ref-type="fig"}). Our assumption was that this condition could mimic in vivo heart rate reduction by strong vagal activation in the presence of a persistent background β-adrenergic activation ([Fig. 8 B](#fig8){ref-type="fig"}). We paced isolated Langendorff-perfused WT and Girk4^−/−^ hearts with 0.1 µM ISO for 5 min to allow the agonist effect to reach steady-state ([Fig. 8 A](#fig8){ref-type="fig"}). We then switched the perfusate to a test solution lacking ISO but containing 0.3 µM ACh and observed the recovery of heart rate to the unstimulated condition before ISO perfusion ([Fig. 8 A](#fig8){ref-type="fig"}). Similarly to what we observed in freely moving mice, recovery of Girk4^−/−^ hearts was significantly delayed in comparison with their WT counterparts (τ~r~ = 23 ± 10 s in *n* = 8 WT and τ~r~ = 101 ± 27 s in *n* = 7 Girk4^−/−^ mice; P \< 0.05; [Fig. 8 A](#fig8){ref-type="fig"}, inset). We then studied the time course of heart rate change upon perfusion of ACh under continuous stimulation by ISO. Under these conditions, ACh slowed pacing of ISO-stimulated WT and Girk4^−/−^ hearts to a similar degree (54 ± 28 bpm and 59 ± 19 bpm in WT and Girk4^−/−^ hearts, respectively; P \> 0.05), but the pacemaker rate of knockout hearts reached steady-state levels after a significantly slower time course (τ~r~ = 24 ± 3 s in *n* = 8 WT and τ~r~ = 84 ± 12 s in *n* = 6 Girk4^−/−^ mice; P \< 0.05; [Fig. 8 B](#fig8){ref-type="fig"}, inset). Collectively, these observations indicate that the delay in heart rate recovery in Girk4^−/−^ mice is a direct consequence of SAN *I~KACh~* ablation.

![Recovery of resting heart rate in isolated WT and Girk4^−/−^ hearts and time course of ACh-induced heart rate reduction under continuous ISO perfusion. (A, left) Basal heart rate (HR) recovery in 0.3 µM ACh after application of 0.1 µM ISO for 5 min in WT (*n* = 8; closed circles) and Girk4^−/−^ (*n* = 7; open circles) Langendorff-perfused hearts. The first data point for each genotype represents heart rate under basal condition, whereas the second data point is the averaged maximal heart rate under ISO, before switching to the solution containing ACh. Dashed lines indicate the basal heart rate before ISO perfusion in WT (black) and Girk4^−/−^ (gray) mice. Continuous lines represent fitting of experimental data points for calculating τ~r~ of recovery. Averaged τ~r~ for WT and Girk4^−/−^ isolated hearts is shown in the insets. (right) Sample ECG traces from WT and Girk4^−/−^ recorded in isolated hearts under resting conditions (before ISO) and 35 s after ACh application. Note that at 35 s in Girk4^−/−^ but not in WT hearts, the pacing rate was still higher than at rest. (B) Similar to A, the first data point is the averaged maximal heart rate with ISO before perfusion. The time course (τ~r~) of rate reduction was calculated during combined perfusion of 0.1 µM ISO and ACh 0.3 µM after maximal stimulation of pacing by ISO in WT (*n* = 8; closed circles) and Girk4^−/−^ (*n* = 6; open circles) hearts. The inset shows averaged τ~r~ for WT and Girk4^−/−^ hearts. Error bars represent SEM. Statistical symbols: \*, P \< 0.05.](JGP_201310996_Fig8){#fig8}

DISCUSSION
==========

We demonstrate that *I~KACh~* is a critical mechanism involved in the muscarinic regulation of SAN pacemaker activity and heart rate regulation after the fight or flight response. Cardiac pacemaker activity is tightly regulated by the autonomic nervous system. Distinct ion channels or intracellular Ca^2+^ handling mechanisms are potentially involved in the parasympathetic control of pacemaker activity and heart rate, but their importance under different physiological conditions is still a matter of debate ([@bib27]; [@bib8]; [@bib22]). In particular, the physiological importance of *I~KACh~* in the autonomic regulation of SAN pacemaking is not completely understood. In atrial myocardium, *I~KACh~* plays an important role in regulating resting membrane potential and action potential repolarization ([@bib17]; [@bib24]). *I~KACh~* activation also favors atrial reentry and triggering of atrial fibrillation by rapid pacing in experimental mammals ([@bib5]) and mice ([@bib20]). Selective block of *I~KACh~* prevents ACh-induced conduction block in the AV node, demonstrating that this current plays an important role in vagal regulation of atrioventricular conduction ([@bib11]). Even if Girk1 and Girk4 subunits are relatively poorly expressed in ventricular tissue in comparison with atrium ([@bib10]), *I~KACh~* can exert a direct negative inotropic effect in ventricular myocytes ([@bib30]), suggesting that this current also regulates the ventricular and Purkinje fiber action potentials in some species.

Here, we showed that genetic inactivation of *I~KACh~* strongly diminishes the cholinergic regulation of SAN pacemaking and reduces the speed of recovery of resting heart rates after physiological tests mimicking the fight or flight response. The expression profile of Girk channel subunits in the mouse SAN is similar to that of the atria ([@bib39]). No mRNA coding for Girk2 or Girk3 subunits could be amplified in PCR experiments of SAN tissue (Fig. S1 A). In contrast, Girk4 immunoreactivity was widely distributed in the SAN, defined as the HCN4-positive region bordered by the caval veins, the crista terminalis, and the interatrial septum ([@bib43]). SAN cells expressing anti-HCN4 immunoreactivity were also positive for Girk4 and Girk1, with strong membrane-bound protein expression as described in larger mammals ([@bib10]). We did not observe residual positive anti-Girk4 immunoreactivity in individual SAN cells within the intact SAN of Girk4^−/−^ hearts. Although SAN cells from knockout hearts exhibited Girk1 immunoreactivity, staining did not appear to be associated with cell membranes. This observation is consistent with the notion that Girk1 subunits cannot form functional channels in the absence of Girk4 ([@bib18]) and that atrial myocytes isolated from Girk4^−/−^ mice do not have residual *I~KACh~* channel activity ([@bib39]). Accordingly, we failed to observe residual *I~KACh~* in SAN cells of Girk4^−/−^ mice ([Fig. 2](#fig2){ref-type="fig"}).

*I~KACh~* loss of function strongly reduced the negative chronotropic effect of ACh in both isolated SAN cells and intact Langendorff-perfused hearts. The pacemaker activity of isolated SAN cells was more sensitive to ACh than that of intact hearts. This difference may result from the "pacemaker shift" phenomenon, in which perfusion of ACh shifts the dominant site of origin of the SAN impulse to groups of cells with lower sensitivity to ACh ([@bib4]). Remarkably, the maximal negative chronotropic effect induced by high doses of ACh (0.3--10 µM) in Girk4^−/−^ hearts did not exceed 20%, whereas WT hearts slowed pacemaking by ∼35--53%. At relatively low agonist concentrations (\<0.3 µM), the ACh-induced negative chronotropic effect was similar between WT and Girk4^−/−^ mice, but heart rate slowing was modest or moderate (5--10%). In this respect, it has been proposed that the muscarinic regulation of heart rate at low vagal tone or ACh concentration depends exclusively on *I~f~* ([@bib9]; [@bib45]; [@bib42]). It is thus possible that negative regulation of *I~f~* current by ACh was responsible, at least in part, for the chronotropic effect observed at low agonist doses observed in our experiments.

The mean daily heart rate of Girk4^−/−^ mice was significantly faster than that of WT mice, irrespective of the relative level of spontaneous activity. Resting heart rates recorded before drug administration or physical tests also showed a trend to elevation in knockout animals. It is important to note that in spite of increased basal heart rates and reduced HRV, the relative degree of rate regulation was similar in WT and Girk4^−/−^ mice. In other words, despite the fact that Girk4^−/−^ mice cannot adjust their heart rate on short time scales ([@bib39]), they can still exhibit fluctuations comparable with those measured in WT controls. This observation suggests that other mechanisms involved in autonomic regulation of SAN pacemaking, such as cAMP-dependent regulation of f-channels ([@bib7]), *I~Ca,L~* ([@bib35]; [@bib45]; [@bib28]), and ryanodine receptor--dependent Ca^2+^ release ([@bib25]; [@bib36]) can sustain a degree of vagal control of pacemaker activity in vivo.

Our experimental data indicate that moderate tachycardia is caused by a loss of tonic inhibition of SAN pacemaking by *I~KACh~* rather than by sympathetic overdrive in knockout mice. First, the rate to activity relationships in WT and Girk4^−/−^ mice were similar, with the degree of heart rate regulation preserved after increasing activity. This observation shows that Girk4^−/−^ mice have a normal range of heart rate control and compliance of the autonomic nervous system. In this respect, the phenotype of Girk4^−/−^ mice clearly differed from that of mice lacking voltage-dependent Ca~v~2.2 Ca^2+^ channels, which show elevated heart rate as the result of increased sympathetic tone and have a strongly reduced range of cardiovascular control ([@bib16]). Second, we recorded similar maximal heart rates and time to recovery of basal rate upon injection of atropine in WT and Girk4^−/−^ mice, although higher heart rates and recovery times would have been expected in the presence of increased background sympathetic tone in knockout animals. Third, the slightly more pronounced effect of β-adrenergic receptor blockade on heart rates of knockout mice is consistent with the hypothesis of reduced muscarinic regulation of SAN pacemaking because the heart rate of WT and Girk4^−/−^ mice should not differ under this condition. In addition, heart rates recorded under β-block should be similar to intrinsic heart hearts after complete autonomic block by combined injection of atropine and propranolol. Both of these conditions are experimentally verified in WT and Girk4^−/−^ mice. Finally, WT and Girk4^−/−^ mice showed similar PR intervals, an observation which shows that sympathetic tone was not appreciably changed in knockout animals.

*I~KACh~* is a critical mechanism involved in recovery of resting heart rate upon stress, physical exercise, or direct pharmacological β-adrenergic activation. Several lines of evidence indicate that such a delay is directly caused by *I~KACh~* loss of function in the heart and not by dysfunction of the autonomic nervous system branches. First, a slower time course in heart rate change could be observed in isolated hearts after maximal β-adrenergic stimulation of pacing rate or under conditions of accentuated antagonism. We did not find evidence of any constitutive reduction in the vagal tone of knockout mice because inhibition of β-adrenergic receptors negated the difference in basal heart rate between WT and Girk4^−/−^ mice. Finally, slowed resting heart rate recovery in Girk4^−/−^ mice was unlikely to be caused by alteration in ionic currents involved in vagal control of heart rate because we found similar *I~f~* and *I~Ca,L~* densities in WT and Girk4^−/−^ SAN cells. The possibility that Girk4^−/−^ mice have major alterations in other ionic currents involved in automaticity is also unlikely because the intrinsic heart rate measured after combined injection of atropine and propranolol did not differ between WT and knockout animals.

The finding that *I~KACh~* is an important mechanism of recovery to resting heart rate was unanticipated. We surmise that recovery of resting heart rate after sympathetic stimulation requires many minutes because down-regulation of cAMP and consequent dephosphorylation of membrane ion channels and/or intracellular Ca^2+^ handling proteins proceed on a slow time scale in the intact SAN. This hypothesis would be consistent with a previous study showing that inhibition of *I~KACh~* with tertiapin reduced the negative chronotropic response to high-frequency vagal stimulation by \>70% in rabbit hearts ([@bib31]). Interestingly, delayed recovery to basal heart rates was observed also after the treadmill test, in which fear responses are less prominent than in swimming tests. This last observation renders it unlikely that the delayed recovery to resting heart rates in Girk4^−/−^ mice is entirely caused by stress hormones. However, an additional possibility is that sympathetic tone remains elevated after stress or forced physical activity for relatively long periods and that *I~KACh~* is an important mechanism to counteract this phenomenon.
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